102 related articles for article (PubMed ID: 10522697)
1. Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists.
Wright JL; Gregory TF; Boxer PA; Meltzer LT; Serpa KA; Wise LD
Bioorg Med Chem Lett; 1999 Oct; 9(19):2815-8. PubMed ID: 10522697
[TBL] [Abstract][Full Text] [Related]
2. Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidines.
Wright JL; Gregory TF; Bigge CF; Boxer PA; Serpa K; Meltzer LT; Wise LD; Cai SX; Hawkinson JE; Konkoy CS; Whittemore ER; Woodward RM; Zhou ZL
J Med Chem; 1999 Jul; 42(13):2469-77. PubMed ID: 10395488
[TBL] [Abstract][Full Text] [Related]
3. Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines.
Wright JL; Gregory TF; Kesten SR; Boxer PA; Serpa KA; Meltzer LT; Wise LD; Espitia SA; Konkoy CS; Whittemore ER; Woodward RM
J Med Chem; 2000 Sep; 43(18):3408-19. PubMed ID: 10978188
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of N-substituted 4-(4-hydroxyphenyl)piperidines, 4-(4-hydroxybenzyl)piperidines, and (+/-)-3-(4-hydroxyphenyl)pyrrolidines: selective antagonists at the 1A/2B NMDA receptor subtype.
Guzikowski AP; Tamiz AP; Acosta-Burruel M; Hong-Bae S; Cai SX; Hawkinson JE; Keana JF; Kesten SR; Shipp CT; Tran M; Whittemore ER; Woodward RM; Wright JL; Zhou ZL
J Med Chem; 2000 Mar; 43(5):984-94. PubMed ID: 10715162
[TBL] [Abstract][Full Text] [Related]
5. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
[TBL] [Abstract][Full Text] [Related]
6. Parallel synthesis of a series of subtype-selective NMDA receptor antagonists.
Gregory TF; Wright JL; Wise LD; Meltzer LT; Serpa KA; Konkoy CS; Whittemore ER; Woodward RM
Bioorg Med Chem Lett; 2000 Mar; 10(6):527-9. PubMed ID: 10741546
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
Nash JE; Brotchie JM
Mov Disord; 2002 May; 17(3):455-66. PubMed ID: 12112191
[TBL] [Abstract][Full Text] [Related]
8. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
Löschmann PA; De Groote C; Smith L; Wüllner U; Fischer G; Kemp JA; Jenner P; Klockgether T
Exp Neurol; 2004 May; 187(1):86-93. PubMed ID: 15081591
[TBL] [Abstract][Full Text] [Related]
9. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
[TBL] [Abstract][Full Text] [Related]
10. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
Warraich ST; Allbutt HN; Billing R; Radford J; Coster MJ; Kassiou M; Henderson JM
Brain Res Bull; 2009 Feb; 78(2-3):85-90. PubMed ID: 18822357
[TBL] [Abstract][Full Text] [Related]
12. Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements.
Schelkun RM; Yuen PW; Serpa K; Meltzer LT; Wise LD; Whittemore ER; Woodward RM
J Med Chem; 2000 May; 43(9):1892-7. PubMed ID: 10794706
[TBL] [Abstract][Full Text] [Related]
13. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions.
Truong L; Allbutt HN; Coster MJ; Kassiou M; Henderson JM
Brain Res Bull; 2009 Feb; 78(2-3):91-6. PubMed ID: 19007866
[TBL] [Abstract][Full Text] [Related]
14. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
[TBL] [Abstract][Full Text] [Related]
15. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
[TBL] [Abstract][Full Text] [Related]
16. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
17. AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
Périer C; Marin C; Bonastre M; Tolosa E; Hirsch EC
Eur J Neurosci; 2002 Dec; 16(11):2236-40. PubMed ID: 12473092
[TBL] [Abstract][Full Text] [Related]
18. Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin-4-ol: a novel NR1/2B subtype selective NMDA receptor antagonist.
Pinard E; Alanine A; Bourson A; Büttelmann B; Gill R; Heitz M; Jaeschke G; Mutel V; Trube G; Wyler R
Bioorg Med Chem Lett; 2001 Aug; 11(16):2173-6. PubMed ID: 11514163
[TBL] [Abstract][Full Text] [Related]
19. 1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists.
Alanine A; Bourson A; Büttelmann B; Gill R; Heitz MP; Mutel V; Pinard E; Trube G; Wyler R
Bioorg Med Chem Lett; 2003 Oct; 13(19):3155-9. PubMed ID: 12951084
[TBL] [Abstract][Full Text] [Related]
20. 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist.
Zhou ZL; Cai SX; Whittemore ER; Konkoy CS; Espitia SA; Tran M; Rock DM; Coughenour LL; Hawkinson JE; Boxer PA; Bigge CF; Wise LD; Weber E; Woodward RM; Keana JF
J Med Chem; 1999 Jul; 42(15):2993-3000. PubMed ID: 10425109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
